Company

Management Management

  • Management
  • Scientific Advisory Board
Samyang  has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies Samyang  has built a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies
CEO Eom, Tae-Woong Profile Image
the CEO Tae-Ung Eom,

After graduating with a degree in chemistry from Sogang University, the CEO, Tae-Ung Eom, worked in the strategic planning field for 35 years as part of the Samyang Group and led a number of major M&A and C&D as a strategic planning specialist within Samyang Group. Since 2015, he has been serving as the CEO of Samyang Biopharm, Inc. and is proceeding with the plan to create and implement a new 2025 VISION.


Chief Stategy Officer의 Helen  Lee Profile Image.
Representative Director of Samyang Biopharm USA
Lee Hyun Jung

Hyun-Jung Helen Lee, representative director of Samyang Biopharm USA, is a gynecologist by training and has been working on the development of anti-cancer drugs for 15 years in Global, the US and the Asia. Previously worked as a global general manager of clinical development of medicine for solid cancer before joining Samyang Group. She has held various executive positions at Baxalta / Baxter and Eli Lilly in the US and also worked as a product physician at Pfizer Korea. After graduating from Yonsei University College of Medicine, she completed her residency training at Severance Hospital, and later, earned her master's degree in Health Care Management at Harvard School of Public Health. Currently, she is in charge of establishing strategies of corporate and R&D and leading clinical development at Samyang Biopharm USA

Biopharmaceutical Research Director Min-hyo Seo Profile Image.
Director of Biopharmaceuticals R&D Center Helen Cho

After earning her Bachelor’s degree from the Department of Biochemistry, Yonsei University and her Master’s degree in bioengineering from KAIST, Dr. Helen Cho acquired her PhD degree in molecular biology and biochemistry from the University of Medicine and Dentistry of New Jersey. Then, she completed her post-doctorate program at Salk Institute and joined Pfizer, a global pharmaceutical company, where she led the development of anticancer immunotherapy drugs based on combination therapy by using her experiences in various fields covering biological carriers and antibodies. As an Associate Research Fellow, she oversaw the research and development (R&D) of anticancer vaccines and oncolytic virus-based immunotherapy drugs as well as early clinical trials. Currently, she serves as the Director of Samyang Holdings Biopharmaceuticals Division R&D Center, supervising R&D in pharmaceuticals, biologics and MD businesses.

Chief Biopharmaceutical Officer Ho-Jun Choi Profile Image.
the director of the pharmaceutical business Lee Yong-jin

Director Lee Yong-jin obtained his Bachelor’s degree from the Department of Biology, Korea University and MBA from Dongguk University Business School. He joined the Samyang Group in 2001, served as Team Leader in Drug Development and Anticancer Drug Sales, and currently supervises pharmaceutical business in Samyang Holdings Biopharmaceuticals. With his career specializing in drug development, sales, and marketing that earned him commendations from the Minister of Health and Welfare and the Minister of Food and Drug Safety, he is overseeing international and Korean businesses.

Chief MD Officer Jae–Doo Lee Profile Image.
the director of MD business Lee Jae-Doo

The director, Lee Jae-doo, received his Bachelor's and Master's degree in chemical engineering from Hanyang University. He joined Samyang in 1993 and is currently working in the field of medical devices. After the release of the medical suture product in 1996, he was in charge of the overseas sales of the medical suture, and contributed greatly to establishing the company's global business base for the suture. Currently, he is directing sales, marketing and the MD plant in the medical device division.

  • The Biologic Therapeutics Center and Radiation Oncology, Washington University, School of Medicine
  • Professor, Graduate School of Medical Science and Engineering, KAIST
  • CEO, PAIJIN BioScience
  • Eshelman School of Pharmacy,University of North Carolina at Chapel Hill.
  • Robert P. Pinkas Family Professor of Bioengineering, School of Engineering and Applied Sciences, Harvard University
  • Core Member, Wyss Institute for Biologically Inspired Engineering at Harvard University
  • Adjunct Investigator, Diabetes Endocrinology Research
  • David T. Curiel, M.D.
    David T. Curiel, M.D.
  •  Eui-Cheol Shin, M.D.
    Eui-Cheol Shin, M.D.
  • The Biologic Therapeutics Center and Radiation Oncology, Washington University, School of Medicine
  • Professor, Graduate School of Medical Science and Engineering, KAIST
  • JinKeon Pai, CEO
    JinKeon Pai, CEO
  • Leaf. Huang, M.D.
    Leaf. Huang, M.D.
  • CEO, PAIJIN BioScience
  • Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.